显示样式:     当前分类: 医药    当前期刊: Annals of Oncology    加入关注    导出
我的关注
我的收藏
您暂时未登录!
登录
  • Multi-Institutional Competing Risks Analysis of Distant Brain Failure and Salvage Patterns after Upfront Radiosurgery without Whole Brain Radiotherapy for Brain Metastasis
    Ann. Oncol. (IF 11.855) Pub Date : 2017-11-17
    E McTyre, D Ayala-Peacock, J Contessa, C Corso, V Chiang, C Chung, J Fiveash, M Ahluwalia, R Kotecha, S Chao, A Attia, A Henson, J Hepel, S Braunstein, M Chan

    In this study we use a competing risks analysis to assess factors predictive of early salvage whole brain radiotherapy (WBRT) and early death after upfront stereotactic radiosurgery (SRS) alone for brain metastases in an attempt to identify populations that benefit less from upfront SRS.

    更新日期:2017-11-17
  • Improved survival in metastatic germ-cell cancer
    Ann. Oncol. (IF 11.855) Pub Date : 2017-11-17
    C D Fankhauser, S Sander, L Roth, J Beyer, T Hermanns

    The prognostic score of the International Germ Cell Cancer Collaborative Group (IGCCCG) in metastatic germ-cell cancers (mGCC) relies on treatments delivered before 1990. It is unclear, if this score is still relevant to contemporary cohorts of patients who receive modern-type chemotherapy and supportive care.

    更新日期:2017-11-17
  • Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study
    Ann. Oncol. (IF 11.855) Pub Date : 2017-11-17
    A Pettersson, D Robinson, H Garmo, L Holmberg, P Stattin

    Old age at prostate cancer diagnosis has been associated with poor prognosis in several studies. We aimed to investigate the association between age at diagnosis and prognosis, and if it is independent of tumor characteristics, primary treatment, year of diagnosis, mode of detection and comorbidity.

    更新日期:2017-11-17
  • Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer; A JSMO - ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
    Ann. Oncol. (IF 11.855) Pub Date : 2017-11-16
    T Yoshino, D Arnold, H Taniguchi, G Pentheroudakis, K Yamazaki, R-H Xu, T W Kim, F Ismail, I B Tan, K-H Yeh, A Grothey, S Zhang, J B Ahn, M.Y. Mastura, D Chong, L-T Chen, S Kopetz, T Eguchi-Nakajima, H Ebi, A Ohtsu, A Cervantes, K Muro, J Tabernero, H Minami, F Ciardiello, J-Y Douillard

    The most recent version of the European Society for Medical Oncology (ESMO) consensus guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was published in 2016, identifying both a more strategic approach to the administration of the available systemic therapy choices, and a greater emphasis on the use of ablative techniques, including surgery. At the 2016 ESMO Asia Meeting, in December 2016, it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting, endorsed by both ESMO and JSMO, immediately after the JSMO 2017 Annual Meeting. The aim was to adapt the ESMO consensus guidelines to take into account the ethnic differences relating to the toxicity as well as other aspects of certain systemic treatments in patients of Asian ethnicity. These guidelines represent the consensus opinions reached by experts in the treatment of patients with mCRC identified by the Presidents of the oncological societies of Japan (JSMO), China (CSCO), Korea (KACO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices and the drug availability and reimbursement situations in the individual participating Asian countries.

    更新日期:2017-11-17
  • Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial
    Ann. Oncol. (IF 11.855) Pub Date : 2017-11-14
    L Buisseret, S Pommey, B Allard, S Garaud, M Bergeron, I Cousineau, L Ameye, Y Bareche, M Paesmans, J P A Crown, A Di Leo, S Loi, M Piccart-Gebhart, K Willard-Gallo, C Sotiriou, J Stagg

    CD73 is an ecto-enzyme that promotes tumor immune escape through the production of immunosuppressive extracellular adenosine in the tumor microenvironment. Several CD73 inhibitors and adenosine receptor antagonists are being evaluated in phase I clinical trials.

    更新日期:2017-11-17
  • Human papillomavirus (HPV) and somatic EGFR mutations are essential, mutually exclusive oncogenic mechanisms for inverted sinonasal papillomas and associated sinonasal squamous cell carcinomas
    Ann. Oncol. (IF 11.855) Pub Date : 2017-11-14
    A M Udager, J B McHugh, C M Goudsmit, H C Weigelin, M S Lim, K S J Elenitoba-Johnson, B L Betz, T E Carey, N A Brown

    Inverted sinonasal papilloma (ISP) is a locally aggressive neoplasm often associated with sinonasal squamous cell carcinoma (SNSCC). While the etiology of ISP is not well understood, human papillomavirus (HPV) has been detected in a subset of cases. Our group recently identified activating somatic EGFR mutations in the majority of ISP and ISP-associated SNSCC. However, the relationship between EGFR mutations and HPV infection has not been explored.

    更新日期:2017-11-17
  • Genotype-based selection of treatment for patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial
    Ann. Oncol. (IF 11.855) Pub Date : 2017-11-14
    A Abad, E Martínez-Balibrea, J M Viéitez, V A Orduña, P García Alfonso, J L Manzano, B Massutí, M Benavides, A Carrato, M Zanui, J Gallego, C Grávalos, V Conde, M Provencio, M Valladares, R Salazar, J Sastre, C Montagut, F Rivera, E Aranda

    There has been little progress toward personalized therapy for patients with metastatic colorectal cancer (mCRC). TYMS-3′ untranslated region (UTR) 6 bp ins/del and ERCC1-118C/T polymorphisms were previously reported to facilitate selecting patients for fluoropyrimidine-based treatment in combination with oxaliplatin as first-line therapy. We assessed the utility of these markers in selecting therapy for patients with mCRC.

    更新日期:2017-11-17
  • The European Society for Medical Oncology (ESMO) Precision Medicine Glossary
    Ann. Oncol. (IF 11.855) Pub Date : 2017-11-13
    L R Yates, J Seoane, C Le Tourneau, L L Siu, R Marais, S Michiels, J C Soria, P Campbell, N Normanno, A Scarpa, J S Reis-Filho, J Rodon, C Swanton, F Andre

    Precision medicine is rapidly evolving within the field of oncology and has brought many new concepts and terminologies that are often poorly defined when first introduced, which may subsequently lead to miscommunication within the oncology community. The European Society for Medical Oncology (ESMO) recognises these challenges and is committed to support the adoption of precision medicine in oncology. To add clarity to the language used by oncologists and basic scientists within the context of precision medicine, the ESMO Translational Research and Personalised Medicine Working Group has developed a standardised glossary of relevant terms.

    更新日期:2017-11-17
  • Multidisciplinary Clinic Approach Improves Overall Survival Outcomes of Patients with Metastatic Germ Cell Tumors
    Ann. Oncol. (IF 11.855) Pub Date : 2017-11-10
    C Albany, N Adra, A C Snavely, C Cary, T A Masterson, R S Foster, K Kesler, T M Ulbright, L Cheng, M Chovanec, F Taza, K Ku, M J Brames, N H Hanna, L H Einhorn

    To report our experience utilizing a multidisciplinary clinic (MDC) at Indiana University (IU) since the publication of the International Germ Cell Cancer Collaborative Group (IGCCCG), and to compare our overall survival to that of the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program.

    更新日期:2017-11-17
  • Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II
    Ann. Oncol. (IF 11.855) Pub Date : 2017-11-06
    I Sestak, S G Smith, A Howell, J F Forbes, J Cuzick

    Anastrozole reduces breast cancer risk in women at high risk, but implementing preventive therapy in clinical practice is difficult. Here, we evaluate adherence to anastrozole in the International Breast Cancer Intervention Study (IBIS) II prevention and Ductal Carcinoma in Situ (DCIS) trials, and its association with early symptoms.

    更新日期:2017-11-17
  • Impact of Neoadjuvant Chemoradiotherapy on Health Related Quality of Life In Long-Term Survivors of Esophageal or Junctional Cancer: Results from the Randomized Cross Trial
    Ann. Oncol. (IF 11.855) Pub Date : 2017-11-06
    B J Noordman, M G E Verdam, S M Lagarde, J Shapiro, M C C M Hulshof, M I van Berge Henegouwen, B P L Wijnhoven, G A P Nieuwenhuijzen, J J Bonenkamp, M A Cuesta, J Th M Plukker, E J Spillenaar Bilgen, E W Steyerberg, A van der Gaast, M A G Sprangers, J J B van Lanschot

    Neoadjuvant chemoradiotherapy (nCRT) plus surgery is a standard of care for patients with esophageal or junctional cancer, but the long-term impact of nCRT on health-related quality of life (HRQOL) is unknown. The purpose of this study is to compare very long-term HRQOL in long-term survivors of esophageal cancer who received nCRT plus surgery or surgery alone.

    更新日期:2017-11-17
  • Circulating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma
    Ann. Oncol. (IF 11.855) Pub Date : 2017-11-03
    R J Lee, G Gremel, A Marshall, K A Myers, N Fisher, J Dunn, N Dhomen, P G Corrie, M R Middleton, P Lorigan, R Marais

    Patients with high-risk stage II/III resected melanoma commonly develop distant metastases. At present, we cannot differentiate between patients who will recur or those who are cured by surgery. We investigated if circulating tumor DNA (ctDNA) can predict relapse and survival in patients with resected melanoma.

    更新日期:2017-11-17
  • Curcumin dietary supplements and everolimus-based cancer treatment
    Ann. Oncol. (IF 11.855) Pub Date : 2017-11-03
    O Mir, S Ropert, A N Chamseddine, A Paci

    The majority of adults in the United States take one or more dietary supplements, either every day or occasionally. Curcuma-containing supplements are broadly used by cancer patients, hoping that curcumin (the main metabolite of curcuma) could exert anticancer effects [1].

    更新日期:2017-11-17
  • Randomized Phase III Trial of Low Molecular Weight Heparin Enoxaparin in Addition to Standard Treatment in Small Cell Lung Cancer: the RASTEN Trial
    Ann. Oncol. (IF 11.855) Pub Date : 2017-11-02
    L Ek, E Gezelius, B Bergman, P O Bendahl, H Anderson, J Sundberg, M Wallberg, U Falkmer, S Verma, M Belting

    Coagulation activation and venous thromboembolism (VTE) are hallmarks of malignant disease and represent a major cause of morbidity and mortality in cancer. Coagulation inhibition with low molecular weight heparin (LMWH) may improve survival specifically in small cell lung cancer (SCLC) patients by preventing VTE and tumor progression; however, randomized trials with well-defined patient populations are needed to obtain conclusive data. The aim of RASTEN was to investigate the survival effect of LMWH enoxaparin in a homogenous population of SCLC patients.

    更新日期:2017-11-17
  • Novel tools to assist neoepitope targeting in personalized cancer immunotherapy
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-30
    S K Saini, N Rekers, S R Hadrup

    Current cancer immunotherapy approaches utilize the remarkable surveillance capacity of the human immune system, which is capable of recognizing and eliminating cancer cells based on identification of tumor-associated antigens arising as a consequence of the transformation process. Among these, mutational-derived neoepitopes have proved to be powerful targets for tumor elimination and mutational load has been shown to correlate with the clinical response to treatment with checkpoint inhibitors in many different tumor types. This suggests a crucial role for neoepitope recognition in T-cell-mediated tumor eradication. Consequently, strategies to further boost neoepitope recognition, through vaccination or adoptive cell transfer, has received substantial interest. Although such strategies have enormous potential, there are also considerable challenges associated with these approaches. In the present review, we will focus on how novel technological developments can facilitate and improve feasibility and efficacy in neoepitope targeting.

    更新日期:2017-11-17
  • Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase 3, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-28
    K Blackwell, P Gascon, A Krendyukov, S Gattu, Y Li, N Harbeck

    In 2015, the biosimilar filgrastim EP2006 became the first biosimilar approved by the US Food and Drug Administration for commercial use in the United States, marketed as Zarxio® (Sandoz). This phase III randomised, double-blind registration study in patients with breast cancer receiving (neo)adjuvant myelosuppressive chemotherapy (TAC; docetaxel + doxorubicin + cyclophosphamide) compares reference filgrastim, Neupogen® (Amgen), with two groups receiving alternating treatment with reference and biosimilar every other cycle.

    更新日期:2017-11-17
  • Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-28
    F Cardoso, J M S Bartlett, L Slaets, C H M van Deurzen, E van Leeuwen-Stok, P Porter, B Linderholm, I Hedenfalk, C Schröder, J Martens, J Bayani, C van Asperen, M Murray, C Hudis, L Middleton, J Vermeij, K Punie, J Fraser, M Nowaczyk, I T Rubio, S Aebi, C Kelly, K J Ruddy, E Winer, C Nilsson, L Dal Lago, L Korde, K Benstead, O Bogler, T Goulioti, A Peric, S Litière, K C Aalders, C Poncet, K Tryfonidis, S H Giordano

    Male breast cancer (BC) is rare, managed by extrapolation from female BC. The International Male BC Program aims to better characterize and manage this disease. We report the results of part I, a retrospective joint analysis of cases diagnosed during a 20-year period.

    更新日期:2017-11-17
  • A Randomized Phase 3 Study Evaluating the Efficacy of Single-dose NEPA, a Fixed Antiemetic Combination of Netupitant and Palonosetron, Versus an Aprepitant Regimen for Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC)
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-28
    L Zhang, S Lu, J Feng, A Dechaphunkul, J Chang, D Wang, S Chessari, C Lanzarotti, K Jordan, M Aapro

    Co-administration of multiple antiemetics that inhibit several molecular pathways involved in emesis is required to optimize CINV control in patients receiving highly emetogenic chemotherapy (HEC). NEPA, a fixed combination of a highly selective NK1 receptor antagonist (RA), netupitant (300 mg), and the pharmacologically distinct 5-HT3RA, palonosetron (PALO 0.50 mg), has shown superior CINV prevention compared to PALO in cisplatin and anthracycline/cyclophosphamide-based settings. This study is the first head-to-head comparison of NEPA versus an aprepitant (APR)/granisetron (GRAN) regimen.

    更新日期:2017-11-17
  • A gene signature to predict high tumour-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple negative breast cancer
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-25
    C Criscitiello, M A Bayar, G Curigliano, F W Symmans, C Desmedt, H Bonnefoi, B Sinn, G Pruneri, C Vicier, J Y Pierga, C Denkert, S Loibl, C Sotiriou, S Michiels, F André

    Introduction: In patients with triple-negative breast cancer (TNBC), the extent of tumor-infiltrating lymphocytes (TILs) in the residual disease (RD) after neoadjuvant chemotherapy (NACT) is associated with better prognosis. Our objective was to develop a gene signature from pre-treatment samples to predict the extent of TILs after NACT, and then to test its prognostic value on survival.

    更新日期:2017-11-17
  • Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: A Retrospective International Study of Invasive/advanced cancer of the urothelium (RISC).
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-25
    A Bamias, K Tzannis, L C Harshman, S J Crabb, Y-N Wong, S Kumar Pal, U De Giorgi, S Ladoire, N Agarwal, E Y Yu, G Niegisch, A Necchi, C N Sternberg, S Srinivas, A Alva, U Vaishampayan, L Cerbone, M Liontos, J Rosenberg, T Powles, J Belmunt, M D Galsky

    Background

    更新日期:2017-11-17
  • Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-24
    Y L Kwong, S J Kim, E Tse, S Y Oh, J Y Kwak, H S Eom, Y R Do, Y C Mun, S R Lee, H J Shin, C Suh, S S Chuang, Y S Lee, S T Lim, K Izutsu, R Suzuki, T Relander, F d’Amore, N Schmitz, A Jaccard, W S Kim

    In stage I/II natural killer (NK)/T-cell lymphoma, concurrent chemoradiotherapy (CCRT) had previously been shown to result in superior outcome compared with anthracycline-containing regimens, which have since been considered ineffective. The role of CCRT in comparison with approaches employing non-anthracycline-containing chemotherapy (CT) and sequential radiotherapy (RT) in such patients remains to be defined.

    更新日期:2017-11-17
  • Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-24
    A Rotte, J Y Jin, V Lemaire

    Checkpoint receptor blockers, known to act by blocking the pathways that inhibit immune cell activation and stimulate immune responses against tumor cells, have been immensely successful in the treatment of cancer. Among several checkpoint receptors of immune cells, cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), programmed cell death protein-1 (PD-1), T-cell immunoglobulin and ITIM domain (TIGIT), T-cell immunoglobulin-3 (TIM-3) and lymphocyte activation gene 3 (LAG-3) are the most commonly targeted checkpoints for cancer immunotherapy. Six drugs including one CTLA-4 blocker (ipilimumab), two PD-1 blockers (nivolumab and pembrolizumab) and three PD-L1 blockers (atezolizumab, avelumab and durvalumab) are approved for the treatment of different types of cancers including both solid tumors such as melanoma, lung cancer, head and neck cancer, bladder cancer and Merkel cell cancer as well as hematological tumors such as classic Hodgkin’s lymphoma. The main problem with checkpoint blockers is that only a fraction of patients respond to the therapy. Insufficient immune activation is considered as one of the main reason for low response rates and combination of checkpoint blockers has been proposed to increase the response rates. The combination of checkpoint blockers was successful in melanoma but had significant adverse events. A combination that is selected based on the mechanistic differences between checkpoints and the differences in expression of checkpoints and their ligands in the tumor microenvironment could have a synergistic effect in a given cancer subtype and also have a manageable safety profile. This review aims to help in design of optimal checkpoint blocker combinations by discussing the mechanistic details and outlining the subtle differences between major checkpoints targeted for cancer immunotherapy.

    更新日期:2017-11-17
  • Ten-year Results of Intense Dose-dense chemotherapy show superior survival compared to a conventional schedule in High-risk Primary Breast Cancer: Final results of AGO Phase III iddEPC trial.
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-24
    V Möbus, C Jackisch, H J Lueck, A du Bois, C Thomssen, W Kuhn, U Nitz, A Schneeweiss, J Huober, N Harbeck, G von Minckwitz, I B Runnebaum, A Hinke, GE Konecny, M Untch, C Kurbacher, S Kahlert, N Hauser, F Marmé, L Kiesel, D Wallwiener, B Rautenberg, R Hofmann, J Barinoff, E Stickeler, H Eidtmann, V Müller, G Emons, P Mallmann, R Hackenberg, C Hielscher, G Räber, H Sommer, P Schmidt-Rhode, B Jahns, A von der Assen, S Dietterle, M Kaufmann, C Strunk, R Goebel, S Paepke, A Paulenz, A Junker-Stein, U Rhein, K Bremer, W Bauer, P Hohlweg-Majert, D Kramer, H-G Meerpohl, K Diedrich, P Dall, H Kölbl, B Brückner, R Gros, H Stehle, K Lobodasch, T Dinkelacker, E Klöpper, C Karg, M Stibora, W Weise, F Melchert, S Mohrmann, C Klatt, M Schmidt, M Glados, H Mickan, A Pollmanns, T Beck, W Schröder, H Klingemann, G Köhler, W Freier, S -T Graßhoff, U Söling, E Keil, C Höß, U Kullmer, A Niesel, H Bodenstein, G Bartzke, C M Schlotter, W Wiest, W Ernst, O Brudler, B Heinrich, J Hackmann, W Niedner, G Hoffmann, W Knapp, G Dresemann, C Karl, F -J Klemm, G C Schliesser, M Butterwegge, H Meden, M Kirschbaum, T Schwenzer, H -J Voigt, U Weiß, G Önder, W Langer, M Glaubitz, M Beha, A Coumbos, Y Ko, J -U Deuker, O Prümmer, U Wagner, A Kohlstedt, P Schreiber, V Jovanovic, K Drzewiecki, H Guba, H Seipt, M Stauch, C Maintz, B Morenz

    Primary breast cancer patients with extensive axillary lymph-node involvement have a limited prognosis. The AGO (Arbeitsgemeinschaft fuer Gynaekologische Onkologie) trial compared intense dose-dense adjuvant chemotherapy with conventionally scheduled chemotherapy in high-risk breast cancer patients. Here we report the final, 10-year follow-up analysis.

    更新日期:2017-11-17
  • The Genomic Grade Index predicts post-operative clinical outcome in patients with soft tissue sarcoma
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-24
    F Bertucci, A De Nonneville, P Finetti, D Perrot, M Nilbert, A Italiano, A Le Cesne, K M Skubitz, J Y Blay, D Birnbaum

    Soft-tissue sarcomas (STS) are a group of rare, heterogeneous and aggressive tumors, with high metastatic risk and relatively few efficient systemic therapies. We hypothesized that the Genomic Grade Index (GGI), a 108-gene signature previously developed in early-stage breast cancer, might improve the prognostic assessment of patients with early-stage STS.

    更新日期:2017-11-17
  • Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-23
    A J Armstrong, E S Antonarakis, M -E Taplin, W K Kelly, H Beltran, K Fizazi, W L Dahut, N Shore, S Slovin, D George, M A Carducci, P Corn, D Danila, R Dreicer, E Heath, D Rathkopf, G Liu, D Nanus, M Stein, M R Smith, C Sternberg, G Wilding, P S Nelson, S Halabi, P Kantoff, N W Clarke, C P Evans, A Heidenreich, N Mottet, M Gleave, M J Morris, H I Scher

    The letter by Pezaro et al. [1] emphasizes a preference for changing nomenclature in prostate cancer, particularly avoiding the terminology ‘castration-resistant prostate cancer’, given that it can be off-putting and objectionable to patients and providers. However, their letter does not frame the taxonomy of the disease accurately; nor does it address the patient benefit derived from appropriately describing the biology for scientific investigation, the regulatory framework for drug development, and how this taxonomy aligns patients, clinicians and researchers in their understanding of the patient’s relevant biology within the continuum of his specific prostate cancer history. As such, until new findings evolve these issues, we advocate retaining the current terminology.

    更新日期:2017-11-17
  • Increase of programmed death ligand 1 in non-small-cell lung cancers with chronic hepatitis B
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-23
    G Lin, W Zhuang, X H Chen, C Huang, X D Lin, Y J Huang, C Li

    Chronic hepatitis B (CHB) is a serious health concern. Accumulated evidence shows that overexpression of programmed death 1 (PD-1), programmed death ligands 1 and 2 (PD-L1 and PD-L2) within the liver and peripheral blood immune cells may be induced by HBeAg or cytokine secretion [1–3]. Blockade of immune check points is a novel treatment for various cancers and PD-L1 expression on tumor cells (TCs) and/or tumor-infiltrating immune cells (ICs) are valuable predictive markers [4]. However, it is unclear whether CHB affects PD-L1 expression in cancer patients with CHB.

    更新日期:2017-11-17
  • Development of leptomeningeal carcinomatosis during a marked response of brain metastases to pembrolizumab in a patient with non-small-cell lung cancer
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-23
    K Otsubo, N Seki, Y Nakanishi, I Okamoto

    Pembrolizumab, a monoclonal antibody to the immune-checkpoint protein PD-1 (programmed cell death-1), has been approved for the treatment of several tumor types including non-small-cell lung cancer (NSCLC). On the basis of the results of a randomized phase III trial (KEYNOTE-024) [1], pembrolizumab is now administered as a standard therapy for patients with advanced NSCLC that expresses the PD-1 ligand (PD-L1) on at least 50% of tumor cells. However, little is known of the efficacy of immune-checkpoint inhibitors (ICIs) for the treatment of central nervous system (CNS) metastasis. We here describe a patient with NSCLC who developed leptomeningeal carcinomatosis despite a marked response of the primary lesion and metastatic brain tumors during pembrolizumab therapy.

    更新日期:2017-11-17
  • A novel pretherapeutic gene expression based risk score for treatment guidance in gastric cancer
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-23
    L Bauer, A Hapfelmeier, S Blank, M Reiche, J Slotta-Huspenina, M Jesinghaus, A Novotny, T Schmidt, B Grosser, M Kohlruss, W Weichert, K Ott, G Keller

    Perioperative chemotherapy is an established treatment of advanced gastric cancer patients. Treatment selection is based on clinical staging (cT). We aimed to establish and validate a prognostic score including clinical and molecular factors, to optimize treatment decisions for these patients.

    更新日期:2017-11-17
  • Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-23
    E Ghorani, R Rosenthal, N McGranahan, J L Reading, M Lynch, K S Peggs, C Swanton, S A Quezada

    Cancer mutations generate novel (neo-) peptides recognised by T-cells, but the determinants of recognition are not well characterised. The difference in predicted class I MHC (MHC-I) binding affinity between wildtype and corresponding mutant peptides (differential agretopicity index; DAI) may reflect clinically relevant cancer peptide immunogenicity. Our aim was to explore the relationship between DAI, measures of immune infiltration and patient outcomes in advanced cancer.

    更新日期:2017-11-17
  • Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-23
    M Overman, L Adam, K Raghav, J Wang, B Kee, D Fogelman, C Eng, E Vilar, R Shroff, A Dasari, R Wolff, J Morris, Enusha Karunasena, R Pisanic, N Azad, S Kopetz

    Hypermethylation of promoter CpG islands (CIMP) represents a unique pathway for the development of colorectal cancer (CRC), characterized by lack of chromosomal instability and a low rate of adenomatous polyposis coli (APC) mutations, which have both been correlated with taxane resistance. Similarly, small bowel adenocarcinoma (SBA), a rare tumor, also has a low rate of APC mutations. This phase II study evaluated taxane sensitivity in SBA and CIMP-high CRC.

    更新日期:2017-11-17
  • A Prospective Genome-Wide Study of Prostate Cancer Metastases Reveals Association of Wnt Pathway Activation and Increased Cell Cycle Proliferation with Primary Resistance to Abiraterone Acetate-Prednisone
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-23
    L Wang, S M Dehm, D W Hillman, H Sicotte, W Tan, M Gormley, V Bhargava, R Jimenez, F Xie, P Yin, S Qin, F Quevedo, B A Costello, H C Pitot, T Ho, A H Bryce, Z Ye, Y Li, P Eiken, P T Vedell, P Barman, B P McMenomy, T D Atwell, R E Carlson, M Ellingson, B Eckloff, R Qin, F Ou, S N Hart, H Huang, J Jen, E D Wieben, K R Kalari, R M Weinshilboum, L Wang, M Kohli

    Genomic aberrations have been identified in metastatic castration-resistant prostate cancer (mCRPC), but molecular predictors of resistance to abiraterone acetate/prednisone (AA/P) treatment are not known.

    更新日期:2017-11-17
  • Understanding personal risk of oropharyngeal cancer: risk-groups for oncogenic oral HPV infection and oropharyngeal cancer
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-19
    G D’Souza, T S McNeel, C Fakhry

    Incidence of human papillomavirus (HPV)-related oropharyngeal cancer is increasing. There is interest in identifying healthy individuals most at risk for development of oropharyngeal cancer to inform screening strategies.

    更新日期:2017-11-17
  • Phase II Trial of Pembrolizumab in Patients with Platinum Refractory Germ Cell Tumors: A Hoosier Cancer Research Network Study GU14-206
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-17
    N Adra, L H Einhorn, S K Althouse, N R Ammakkanavar, D Musapatika, C Albany, D Vaughn, N H Hanna

    Despite remarkable results with salvage standard-dose or high-dose chemotherapy ∼15% of patients with relapsed germ-cell tumors (GCT) are incurable. Immune checkpoint inhibitors have produced significant remission in multiple tumor types. We report the first study of immunotherapy in patients with GCT.

    更新日期:2017-11-17
  • Emerging treatment paradigms in brain metastasis in non-small cell lung cancer: an overview of the current landscape and challenges ahead.
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-17
    D Ulahannan, J Khalifa, C Faivre-Finn, S M Lee

    Advances in the last decade in genomic profiling and the identification of druggable targets amenable to biological agents have transformed the management and survival of a subgroup of patients with brain metastasis in non-small-cell lung cancer. In parallel, clinicians have reevaluated the role of whole brain radiotherapy in selected patients with brain metastases to reduce neurocognitive toxicity. Continual progress in this understudied field is required: optimization of the sequence of schedules for therapies in patients with brain metastases of differing genomic profiles, focusing on new strategies to overcome mechanisms of biological resistance and increasing drug penetrability into the central nervous system. This review summarizes the field to date and possible treatment strategies based on current evidence.

    更新日期:2017-11-17
  • The Warburg effect: persistence of stem cell metabolism in cancers as a failure of differentiation
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-13
    M Riester, Q Xu, A Moreira, J Zheng, F Michor, R J Downey

    Two recent observations regarding the Warburg effect are that (i) the metabolism of stem cells is constitutive (aerobic) glycolysis while normal cellular differentiation involves a transition to oxidative phosphorylation and (ii) the degree of glucose uptake of a malignancy as imaged by 18F-fluorodeoxyglucose positron emission tomography (FDG–PET) is associated with histologic measures of tumor differentiation. Combining these observations, we hypothesized that the high levels of glucose uptake observed in poorly differentiated cancers may reflect persistence of the glycolytic metabolism of stem cells in malignant cells that fail to fully differentiate.

    更新日期:2017-11-17
  • A predictive model of pathological response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-12
    P Nuciforo, T Pascual, J Cortés, A Llombart-Cussac, R Fasani, L Paré, M Oliveira, P Galvan, N Martínez, B Bermejo, M Vidal, S Pernas, R López, M Muñoz, I Garau, L Manso, J Alarcón, E Martínez, V Rodrik-Outmezguine, J C Brase, P Villagrasa, A Prat, E Holgado

    The presence of stromal tumor-infiltrating lymphocytes (TILs) is associated with increased pathological complete response (pCR) and improved outcomes in HER2-positive early breast cancer (BC) treated with anti-HER2-based chemotherapy. In the absence of chemotherapy, the association of TILs with pCR following anti-HER2 therapy-only is largely unknown.

    更新日期:2017-11-17
  • Stevens–Johnson syndrome during nivolumab treatment of NSCLC
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-12
    M Salati, M Pifferi, C Baldessari, F Bertolini, C Tomasello, S Cascinu, F Barbieri

    Stevens–Johnson syndrome (SJS) is a type IV hypersensitivity reaction, mainly to drugs, that presents as mucocutaneous blistering and sloughing and which may follow a devastating clinical course. Although its incidence is roughly 1–2 cases per million/year, the mortality rate may be as high as 30% when the condition progresses to toxic epidermal necrolysis (TEN; also known as Lyell’s syndrome). Many different drug classes have been implicated as causes of SJS (e.g. antibiotics, NSAIDs, anticonvulsants) [1]. Among them, immune checkpoint inhibitors, such as the anti-PD1 agent nivolumab, are emerging culprits. This is especially relevant considering that the use of such drugs in oncology is becoming more widespread in an ever-increasing number of cancer types. It has recently been reported that up to 22%...

    更新日期:2017-11-17
  • Reply to the letter to the editor ‘Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?’ by Del Paggio
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-12
    N I Cherny, U Dafni, J Bogaerts, N J Latino, G Pentheroudakis, J -Y Douillard, J Tabernero, C Zielinski, M J Piccart, E G E de Vries

    We appreciated Dr Del Paggio’s continuing interest in the ESMO-MCBS [1]. In Form 2a of the ESMO-MCBS, which scales studies with evidence of benefit in overall survival, the ESMO-MCBS provides a 1 point bonus if the newer treatment is associated with fewer adverse events that undermine daily well-being. We acknowledge the inconsistency in the language used in Form 2a whereby statistical significance is referred to in the trigger question regarding toxicity (‘Are there statistically significantly less grade 3–4 toxicities impacting on daily well-being?’) but not in the adjustment criteria (‘Upgrade 1 level if improved quality of life and/or less grade 3–4 toxicities impacting daily well-being are shown’). It is understandable that this may contribute to confusion in applying the form.

    更新日期:2017-11-17
  • Not only tumor but also therapy heterogeneity
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-12
    S Garattini, I Fuso Nerini, M D’Incalci

    Tumor heterogeneity is a recurrent concept as well as a frequent keyword in modern oncology. However, it has long been known that solid tumors originating from the same organ often show morphologic variability [1]. For certain tumors, the histologic phenotype and the degree of differentiation have prognostic significance, although they are usually of limited value in deciding the best therapeutic intervention, which is mainly based on the clinical stage. However, certain aspects of molecular heterogeneity are certainly of greater significance from a therapeutic point of view. For example, the estrogen receptor detection in breast cancer led to the selection of cases benefiting from antiestrogen treatments [2]. Identification of specific molecular alterations in tumors has resulted in targeted therapeutic approaches based...

    更新日期:2017-11-17
  • The predictive value of interim FDG-PET in early-stage Hodgkin lymphoma is not well established
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-11
    H J A Adams, T C Kwee

    A recent study by Zaucha et al. [1] included 106 patients with early-stage Hodgkin lymphoma. These patients were treated with 2–4 cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) or with six cycles of ABVD. These patients underwent interim FDG-PET scans after one cycle of ABVD in all 106 cases, whereas 57 (53.8%) underwent FDG-PET imaging both after one and two cycles of ABVD. After one cycle of ABVD, FDG-PET scans of 87/106 (82%) patients were scored negative (i.e. Deauville score 1–3), whereas 19/106 (18%) were scored positive (i.e. Deauville score 4–5), of whom four were excluded from further analysis because of progression and treatment escalation. Of the patients with negative interim FDG-PET results, 4/87 had an...

    更新日期:2017-11-17
  • Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-11
    M H Pollack, A Betof, H Dearden, K Rapazzo, I Valentine, A S Brohl, K K Ancell, G V Long, A M Menzies, Z Eroglu, D B Johnson, A N Shoushtari

    Combined cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1) blockade induces high rates of immune-related adverse events (irAEs). The safety of resuming anti-PD-1 in patients who discontinue combination therapy due to irAEs is not known.

    更新日期:2017-11-17
  • Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-10
    S Jain, C A Lyons, S M Walker, S McQuaid, S Hynes, D Mitchell, B Pang, G E Logan, A M McCavigan, D O’Rourke, D McArt, S McDade, I Mills, K M Prise, L A Knight, C J Steele, P W Medlow, V Berge, B Katz, D A Loblaw, D P Harkin, J James, J M O’Sullivan, R D Kennedy, D J Waugh

    Radiotherapy is an effective treatment of intermediate/high-risk locally advanced prostate cancer, however, >30% of patients relapse within 5 years. Clinicopathological parameters currently fail to identify patients prone to systemic relapse and those whom treatment intensification may be beneficial. The purpose of this study was to independently validate the performance of a 70-gene Metastatic Assay in a cohort of diagnostic biopsies from patients treated with radical radiotherapy and androgen deprivation therapy.

    更新日期:2017-11-17
  • Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-10
    M Lambertini, O Goldrat, A R Ferreira, J Dechene, H A Azim Jr, J Desir, A Delbaere, M-D t’Kint de Roodenbeke, E de Azambuja, M Ignatiadis, I Demeestere

    Preclinical evidence suggests a possible negative impact of deleterious BRCA mutations on female fertility. However, limited and rather conflicting clinical data are available. This study assessed the reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients.

    更新日期:2017-11-17
  • Patient and tumor characteristics and their influence on early therapy persistence with letrozole in postmenopausal patients with early breast cancer
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-10
    N Nabieva, S Kellner, T Fehm, L Häberle, J de Waal, M Rezai, B Baier, G Baake, H-C Kolberg, M Guggenberger, M Warm, N Harbeck, R Wuerstlein, J-U Deuker, P Dall, B Richter, G Wachsmann, C Brucker, J W Siebers, N Fersis, T Kuhn, C Wolf, H-W Vollert, G-P Breitbach, W Janni, R Landthaler, A Kohls, D Rezek, T Noesselt, G Fischer, S Henschen, T Praetz, V Heyl, T Kühn, T Krauss, C Thomssen, A Hohn, H Tesch, C Mundhenke, A. Hein, C Rauh, C M Bayer, A Jacob, K Schmidt, E Belleville, S Y Brucker, S Kümmel, M W Beckmann, D Wallwiener, P Hadji, P A Fasching

    Patients’ compliance and persistence with endocrine treatment has a significant effect on the prognosis in early breast cancer (EBC). The purpose of this analysis was to identify possible reasons for non-persistence, defined as premature cessation of therapy, on the basis of patient and tumor characteristics in individuals receiving adjuvant treatment with letrozole.

    更新日期:2017-11-17
  • Liquid biopsy: another tool towards tailored therapy in colorectal cancer
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-10
    N Tarazona, A Cervantes

    Colorectal cancer (CRC) is an important public health issue, being the second leading cause of cancer death worldwide [1, 2]. Although the prognosis of patients with CRC has improved during the past decades, almost half of all CRC patients with localized disease will relapse after initial treatment. Even so, the median survival time for patients with metastatic CRC (mCRC) is about 30 months [3].

    更新日期:2017-11-17
  • From hepatitis C virus infection to B-cell lymphoma
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-10
    L Couronné, E Bachy, S Roulland, B Nadel, F Davi, M Armand, D Canioni, J M Michot, C Visco, L Arcaini, C Besson, O Hermine

    In addition to liver disorders, hepatitis C virus (HCV) is also associated with extrahepatic immune manifestations and B-cell non-Hodgkin lymphoma (NHL), especially marginal zone lymphoma, de novo or transformed diffuse large B-cell lymphoma and to a lesser extent, follicular lymphoma. Epidemiological data and clinical observations argue for an association between HCV and lymphoproliferative disorders. The causative role of HCV in NHL has been further supported by the response to antiviral therapy. Pathophysiological processes at stake leading from HCV infection to overt lymphoma still need to be further elucidated. Based on reported biological studies, several mechanisms of transformation seem however to emerge. A strong body of evidence supports the hypothesis of an indirect transformation mechanism by which sustained antigenic stimulation leads from oligoclonal to monoclonal expansion and sometimes to frank lymphoma, mostly of marginal zone subtype. By infecting lymphocytes, HCV could play a direct role in cellular transformation, particularly in de novo large B-cell lymphoma. Finally, HCV is associated with follicular lymphoma in a subset of patients. In this setting, it may be hypothesized that inflammatory cytokines stimulate proliferation and transformation of IgH–BCL2 clones that are increased during chronic HCV infection. Unraveling the pathogenesis of HCV-related B-cell lymphoproliferation is of prime importance to optimize therapeutic strategies, especially with the recent development of new direct-acting antiviral drugs.

    更新日期:2017-11-17
  • The use of antidepressants in oncology: a review and practical tips for oncologists
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-09
    L Grassi, M G Nanni, G Rodin, M Li, R Caruso

    The use of psychotropic drugs, namely those with an antidepressant profile (ADs), is a mandatory part of an integrated treatment of psychiatric disorders among cancer patients. We aimed to synthetize the most relevant data emerging from published studies to provide tips about the use of ADs in oncology.

    更新日期:2017-11-17
  • Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-09
    S Y Moorcraft, D Gonzalez de Castro, D Cunningham, T Jones, B A Walker, C Peckitt, L C Yuan, M Frampton, R Begum, Z Eltahir, A Wotherspoon, L S Teixeira Mendes, S Hulkki Wilson, A Gillbanks, C Baratelli, N Fotiadis, A Patel, C Braconi, N Valeri, M Gerlinger, S Rao, D Watkins, I Chau, N Starling

    Targeted capture sequencing can potentially facilitate precision medicine, but the feasibility of this approach in gastrointestinal (GI) malignancies is unknown.

    更新日期:2017-11-17
  • Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small cell lung cancer
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-09
    M Ilié, E Szafer-Glusman, V Hofman, E Chamorey, S Lalvée, E Selva, S Leroy, C-H Marquette, M Kowanetz, P Hedge, E Punnoose, P Hofman

    Expression of PD-L1 in tumor cells and tumor-infiltrating immune cells has been associated with improved efficacy to anti-PD-1/PD-L1 inhibitors in patients with advanced-stage non-small-cell lung cancer (NSCLC) and emerged as a potential biomarker for the selection of patients to cancer immunotherapies. We investigated the utility of circulating tumor cells (CTCs) and circulating white blood cells (WBCs) as a noninvasive method to evaluate PD-L1 status in advanced NSCLC patients.

    更新日期:2017-11-17
  • Refractory or relapsed aggressive B-cell lymphoma failing (R)-CHOP: An analysis of patients treated on the RICOVER-60 trial
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-06
    B Glass, A J Dohm, L H Truemper, M Pfreundschuh, A Bleckmann, G G Wulf, A Rosenwald, M Ziepert, N Schmitz

    The prognosis of elderly patients with aggressive B-non-Hodgkin’s lymphoma after first lymphoma-related treatment failure (TF-L) is not well described.

    更新日期:2017-11-17
  • DPYD genotype-guided fluoropyrimidines dose: is it ready for prime time?
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-05
    D Páez, R Salazar, J Tabernero

    For over 50 years, fluoropyrimidines have been the cornerstone of anticancer drugs for various types of solid cancers. Treatment with these drugs—5-fluorouracil (FU) and its oral prodrugs, capecitabine and tegafur—is generally well-tolerated, except in a small proportion of patients who develop severe and life-threatening early toxicity. This toxicity is mainly associated with a deficiency of the primary fluoropyrimidine detoxifying enzyme, dihydropryrimidine dehydrogenase (DPD) [1]. The drug labels of FU and capecitabine state DPD deficiency as a contraindication, but they give no warning for the 3%–8% of the population who are partially DPD deficient.

    更新日期:2017-11-17
  • Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-04
    Charlotte Fribbens, Isaac Garcia Murillas, Matthew Beaney, Sarah Hrebien, Ben O’Leary, Lucy Kilburn, Karen Howarth, Michael Epstein, Emma Green, Nitzan Rosenfeld, Alistair Ring, Stephen Johnston, Nicholas Turner

    Selection of resistance mutations may play a major role in the development of endocrine resistance. ESR1 mutations are rare in primary breast cancer but have high prevalence in patients treated with aromatase inhibitors (AI) for advanced breast cancer. We investigated the evolution of genetic resistance to the first-line AI therapy using sequential ctDNA sampling in patients with advanced breast cancer.

    更新日期:2017-11-17
  • SELECT-2: a Phase II, double-blind, randomised, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment for patients with advanced or metastatic non-small cell lung cancer
    Ann. Oncol. (IF 11.855) Pub Date : 2017-10-03
    JC Soria, A Fülöp, C Maciel, J R Fischer, G Girotto, S Lago, E Smit, G Ostoros, W E E Eberhardt, P Lishkovska, S Lovick, G Mariani, A McKeown, E Kilgour, P Smith, K Bowen, A Kohlmann, D J Carlile, P A Jänne

    Combination of selumetinib plus docetaxel provided clinical benefit in a previous phase II trial for patients with KRAS-mutant advanced non-small-cell lung cancer (NSCLC). The phase II SELECT-2 trial investigated safety and efficacy of selumetinib plus docetaxel for patients with advanced or metastatic NSCLC.

    更新日期:2017-11-17
  • Veliparib With Temozolomide or Carboplatin/Paclitaxel Versus Placebo With Carboplatin/Paclitaxel in Patients With BRCA1/2 Locally Recurrent/Metastatic Breast Cancer: Randomized Phase II Study
    Ann. Oncol. (IF 11.855) Pub Date : 2017-09-29
    H.S. Han, V. Diéras, M. Robson, M. Palácová, P. K. Marcom, A. Jager, I. Bondarenko, D. Citrin, M. Campone, M. L. Telli, S. M. Domchek, M. Friedlander, B. Kaufman, J. E. Garber, Y. Shparyk, E. Chmielowska, E. H. Jakobsen, V. Kaklamani, W. Gradishar, C. K. Ratajczak, C. Nickner, Q. Qin, J. Qian, S. P. Shepherd, S. J. Isakoff, S. Puhalla

    Homologous recombination defects in BRCA1/2-mutated tumors result in sensitivity to poly(ADP-ribose) polymerase inhibitors, which interfere with DNA damage repair. Veliparib, a potent poly(ADP-ribose) polymerase inhibitor, enhanced the antitumor activity of platinum agents and temozolomide in early phase clinical trials. This phase II study examined the safety and efficacy of intermittent veliparib with carboplatin/paclitaxel (VCP) or temozolomide (VT) in patients with BRCA1/2-mutated breast cancer.

    更新日期:2017-11-17
  • Surgery for patients with ‘lower grade’ glioma: putting assumptions, beliefs and convictions into perspective
    Ann. Oncol. (IF 11.855) Pub Date : 2017-09-28
    M Weller

    Annals of Oncology 2017:00:1-2. doi:10.1093/annonc/mdx295

    更新日期:2017-11-17
  • Gougerot-Sjogren-like syndrome under PD-1 inhibitor treatment
    Ann. Oncol. (IF 11.855) Pub Date : 2017-09-28
    D. Teyssonneau, S. Cousin, A. Italiano

    A 36-year-old female patient with no significant medical history except hypothyroidism was diagnosed with left parotid acinic cell carcinoma that was treated by radical parotidectomy followed by adjuvant radiotherapy (50 Gy) in 2004. Seven years after the initial diagnosis, the patient developed histologically confirmed metastases on the left adrenal gland and the lung, for which systemic therapy was indicated. The patient participated in two successive studies and received lapatinib and then an EZH-2 inhibitor. In March 2016, the patient’s adrenal lesion progressed, and she started treatment with pembrolizumab, 200 mg, every 3 weeks. At the time of the 11th injection, the patient experienced a retinal detachment that was linked to her myopia. The detachment was treated by surgery and amoxicillin for 7 days. Subsequently,...

    更新日期:2017-11-17
  • Bevacizumab + chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial - PRODIGE 20 study results
    Ann. Oncol. (IF 11.855) Pub Date : 2017-09-28
    T. Aparicio, O. Bouché, J Taieb, E. Maillard, S. Kirscher, P.-L. Etienne, R. Faroux, F. Akouz Khemissa, F. El Hajbi, C. Locher, Y. Rinaldi, T. Lecomte, S. Lavau-Denes, M. Baconnier, A. Oden-Gangloff, D. Genet, E. Paillaud, F. Retornaz, E. François, L. Bedenne

    Metastatic colorectal cancer frequently occurs in elderly patients. Bevacizumab in combination with front line chemotherapy is a standard treatment but some concern raised about tolerance of bevacizumab for these patients. The purpose of PRODIGE 20 was to evaluate tolerance and efficacy of bevacizumab according to specific endpoints in this population.

    更新日期:2017-11-17
  • Molecular Tumor Boards: Current Practice and Future Needs
    Ann. Oncol. (IF 11.855) Pub Date : 2017-09-27
    D.L. van der Velden, C.M.L. van Herpen, H.W.M. van Laarhoven, E.F. Smit, H.J.M. Groen, S.M. Willems, P.M. Nederlof, M.H.G. Langenberg, E. Cuppen, S. Sleijfer, N. Steeghs, E.E. Voest

    Due to rapid technical advances, steeply declining sequencing costs, and the ever-increasing number of targeted therapies, it can be expected that extensive tumor sequencing such as whole-exome and whole-genome sequencing will soon be applied in standard care. Clinicians will thus be confronted with increasingly complex genetic information and multiple test-platforms to choose from. General medical training, meanwhile, can hardly keep up with the pace of innovation. Consequently, there is a rapidly growing gap between clinical knowledge and genetic potential in cancer care. Multidisciplinary Molecular Tumor Boards (MTBs) have been suggested as a means to address this disparity, but shared experiences are scarce in literature and no quality requirements or guidelines have been published to date.

    更新日期:2017-11-17
  • Clinical and molecular characterization of patients with cancers of unknown primary in the modern era
    Ann. Oncol. (IF 11.855) Pub Date : 2017-09-26
    A.M. Varghese, A. Arora, M. Capanu, N. Camacho, H.H. Won, A. Zehir, J. Gao, D. Chakravarty, N. Schultz, D.S. Klimstra, M. Ladanyi, D.M. Hyman, D.B. Solit, M.F. Berger, L.B. Saltz

    On the basis of historical data, patients with cancer of unknown primary (CUP) are generally assumed to have a dismal prognosis with overall survival of less than 1 year. Treatment is typically cytotoxic chemotherapy guided by histologic features and the pattern of metastatic spread. The purpose of this study was to provide a clinical and pathologic description of patients with CUP in the modern era, to define the frequency of clinically actionable molecular alterations in this population, to determine how molecular testing can alter therapeutic decisions, and to investigate novel uses of next-generation sequencing in the evaluation and treatment of patients with CUP.

    更新日期:2017-11-17
  • Clinical benefit of systemic treatment in patients with advanced pancreatic and gastro-intestinal neuroendocrine tumours according to ESMO-MCBS and ASCO framework
    Ann. Oncol. (IF 11.855) Pub Date : 2017-09-26
    L.D. de Hosson, L.M. van Veenendaal, Y. Schuller, W.T. Zandee, W.W. de Herder, M.E.T. Tesselaar, H.J. Klümpen, A.M.E. Walenkamp

    Assessment of clinical benefit of systemic treatments of rare diseases including gastroenteropancreatic neuroendocrine tumours (GEP-NET) is challenging. Recently several tools have been developed to grade the clinical benefit of cancer drugs. The European Society for Medical Oncology (ESMO) has developed the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS). The American Society of Clinical Oncology (ASCO) has developed and revised the ASCO framework consisting of the Net Health Benefit (NHB) score juxtaposed against the costs of the treatment. In this review, we graded systemic treatments for GEP-NET patients with both frameworks.

    更新日期:2017-11-17
Some contents have been Reproduced with permission of the American Chemical Society.
Some contents have been Reproduced by permission of The Royal Society of Chemistry.
所有期刊列表A-Z